Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Status:
Recruiting
Trial end date:
2029-01-31
Target enrollment:
Participant gender:
Summary
Follicular lymphoma (FL) has a number of effective standard of care therapies; however, FL is
not currently considered curable. Therefore, designing well tolerated therapies without
cumulative and long-term toxicity is critical. This is a pilot safety and feasibility study
that combines a personalized tumor vaccine with nivolumab for the treatment of FL. Patients
who demonstrate progression on this study may be treated with rituximab (or another
monoclonal antibody against CD20) in addition to vaccine therapy with nivolumab at the
discretion of treating physician if clinically indicated.